Matthew R. Brier MD, PhD, Suzanne E. Schindler, Amber Salter, Dana Perantie, Nicole Shelley, Bradley Judge, Sarah Keefe, Kristopher M. Kirmess, Philip B. Verghese PhD, Kevin E. Yarasheski, Venky Venkatesh, Cyrus A. Raji, Brian A. Gordon, Randall J. Bateman, John C. Morris, Robert T. Naismith, David M. Holtzman, Tammie L.S. Benzinger, Anne H. Cross
{"title":"Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients","authors":"Matthew R. Brier MD, PhD, Suzanne E. Schindler, Amber Salter, Dana Perantie, Nicole Shelley, Bradley Judge, Sarah Keefe, Kristopher M. Kirmess, Philip B. Verghese PhD, Kevin E. Yarasheski, Venky Venkatesh, Cyrus A. Raji, Brian A. Gordon, Randall J. Bateman, John C. Morris, Robert T. Naismith, David M. Holtzman, Tammie L.S. Benzinger, Anne H. Cross","doi":"10.1002/ana.27027","DOIUrl":null,"url":null,"abstract":"<p>The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453–459</p>","PeriodicalId":127,"journal":{"name":"Annals of Neurology","volume":null,"pages":null},"PeriodicalIF":8.1000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ana.27027","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The life expectancy of people with multiple sclerosis (MS) has increased, yet we have noted that development of a typical Alzheimer disease dementia syndrome is uncommon. We hypothesized that Alzheimer disease pathology is uncommon in MS patients. In 100 MS patients, the rate of amyloid-β plasma biomarker positivity was approximately half the rate in 300 non-MS controls matched on age, sex, apolipoprotein E proteotype, and cognitive status. Interestingly, most MS patients who did have amyloid-β pathology had features atypical for MS at diagnosis. These results support that MS is associated with reduced Alzheimer disease risk, and suggest new avenues of research. ANN NEUROL 2024;96:453–459
期刊介绍:
Annals of Neurology publishes original articles with potential for high impact in understanding the pathogenesis, clinical and laboratory features, diagnosis, treatment, outcomes and science underlying diseases of the human nervous system. Articles should ideally be of broad interest to the academic neurological community rather than solely to subspecialists in a particular field. Studies involving experimental model system, including those in cell and organ cultures and animals, of direct translational relevance to the understanding of neurological disease are also encouraged.